T-cell prolymphocytic leukemia surgery: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 2: | Line 2: | ||
{{T-cell prolymphocytic leukemia}} | {{T-cell prolymphocytic leukemia}} | ||
{{CMG}}; {{AE}}{{Qurrat}}, {{MV}} | {{CMG}}; {{AE}}{{Qurrat}}, {{MV}} | ||
==Overview== | |||
==Surgery== | |||
*Autologous and allogeneic stem cell transplants is the mainstay of therapy for patients who achieve remission. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} |
Revision as of 17:15, 26 March 2019
T-cell prolymphocytic leukemia Microchapters |
Differentiating T-cell prolymphocytic leukemia historical perspective from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
T-cell prolymphocytic leukemia surgery On the Web |
American Roentgen Ray Society Images of T-cell prolymphocytic leukemia surgery |
Risk calculators and risk factors for T-cell prolymphocytic leukemia surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Qurrat-ul-ain Abid, M.D.[2], Maria Fernanda Villarreal, M.D. [3]
Overview
Surgery
- Autologous and allogeneic stem cell transplants is the mainstay of therapy for patients who achieve remission.